Vericel announced that it has secured a $197 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for its burn‑debridement product NexoBrid. The contract, effective April 1, 2026, spans ten years and includes a base period of $35 million, of which roughly $10 million is earmarked for initial procurement for the Strategic National Stockpile and the establishment of a vendor‑managed inventory (VMI) system.
The agreement covers several key objectives: procurement of NexoBrid, design and validation of a U.S.‑based manufacturing facility, development of a next‑generation formulation, and exploration of a new indication for blast‑trauma injuries. Optional awards allow for additional procurement, further clinical development, and the creation of a room‑temperature stable formulation. The contract’s structure provides Vericel with a predictable, long‑term revenue stream while also advancing product innovation and domestic manufacturing capabilities.
Vericel’s President and CEO Nick Colangelo said the partnership “demonstrates the significant clinical value of NexoBrid and will support the continued expansion of NexoBrid utilization in the U.S.” The announcement follows a history of BARDA support for NexoBrid, including prior procurements totaling $16.5 million and $56 million for development, and a $0.2 million revenue in Q1 2022 from BARDA sales. Although the new contract’s revenue is not yet reflected in Vericel’s 2026 guidance, management indicated a “reasonable possibility” that incremental revenue could be recognized in the coming years.
Strategically, the contract aligns with U.S. national preparedness for mass‑casualty burn and blast events, positioning Vericel as a key partner in emergency response. The domestic manufacturing component reduces reliance on overseas production and could improve supply chain resilience. The next‑generation formulation and blast‑trauma indication represent potential market expansion, while the VMI system enhances distribution efficiency for future procurement cycles.
Overall, the BARDA contract represents a significant milestone for Vericel, providing both immediate financial support and long‑term growth opportunities through product development, manufacturing expansion, and strengthened national security partnerships.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.